Valuation in Life Sciences | A Practical Guide

Boris Bogdan (u. a.)

ISBN 10: 3642425844 / ISBN 13: 9783642425844

Published by Springer, 2014

About this Item

Valuation in Life Sciences | A Practical Guide | Boris Bogdan (u. a.) | Taschenbuch | xiv | Englisch | 2014 | Springer | EAN 9783642425844 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Seller Inventory # 104914163

Bibliographic Details

• Title: Valuation in Life Sciences | A Practical Guide
• Publisher: Springer
• Publication Date: 2014
• Language: English
• ISBN 10: 3642425844
• ISBN 13: 9783642425844
• Binding: Taschenbuch
• Edition: 3rd Edition
• Condition: Neu
• Dimensions: 235W x 155H x 21D millimeters 235 millimeters width by 155 millimeters height by 21 millimeters depth
• Weight: 581 grams
• Seller catalogs:
  • Bücher

About this title

Synopsis

This book offers a complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including discounted cash-flow and real options, the authors demonstrate how to value projects, patents, licenses, firms and stocks on real-life examples, even treating complex license and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.

From the Back Cover

This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including DCF, decision trees, and real options, the authors demonstrate how to value projects, patents, licences, firms, and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.

The 3^rd edition of the successful work includes new studies about success rates and about drug development in the biotech industry and their influence on valuation.